Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 416

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Open access
Goyal, Gaurav, Heaney, Mark L., Collin, Matthew, Cohen-Aubart, Fleur, Vaglio, Augusto, Durham, Benjamin H., Hershkovitz-Rokah, Oshrat, Girschikofsky, Michael, Jacobsen, Eric D., Toyama, Kazuhiro, Goodman, Aaron M., Hendrie, Paul, Cao, Xin-xin, Estrada-Veras, Juvianee I., Shpilberg, Ofer, Abdo, André, Kurokawa, Mineo, Dagna, Lorenzo, McClain, Kenneth L., Mazor, Roei D., Picarsic, Jennifer, Janku, Filip, Go, Ronald S., Haroche, Julien, Diamond, Eli L.·2020·Blood

Abstract

Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK (RAS-RAF-MEK-ERK) pathway mutations. Typical findings of ECD include central diabetes insipidus, restrictive pericarditis, perinephric fibrosis, and sclerotic bone lesions. The histopathologic diagnosis of ECD is often challenging due to nonspecific inflammatory and fibrotic findings on histopathologic review of tissue specimens. Additionally, the association of ECD with unusual tissue tropism and an insidious onset often results in diagnostic errors and delays. Most patients with ECD require treatment, except for a minority of patients with minimally symptomatic single-organ disease. The first ECD consensus guidelines were published in 2014 on behalf of the physicians and researchers within the Erdheim-Chester Disease Global Alliance. With the recent molecular discoveries and the approval of the first targeted therapy (vemurafenib) for BRAF-V600–mutant ECD, there is a need for updated clinical practice guidelines to optimize the diagnosis and treatment of this disease. This document presents consensus recommendations that resulted from the International Medical Symposia on ECD in 2017 and 2019. Herein, we include the guidelines for the clinical, laboratory, histologic, and radiographic evaluation of ECD patients along with treatment recommendations based on our clinical experience and review of literature in the molecular era.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2019003507

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 416

Metadata

Authors
Goyal, G., Heaney, M. L., Collin, M., Cohen-Aubart, F., Vaglio, A., Durham, B. H., Hershkovitz-Rokah, O., Girschikofsky, M., Jacobsen, E. D., Toyama, K., Goodman, A. M., Hendrie, P., Cao, X.-X., Estrada-Veras, J. I., Shpilberg, O., Abdo, A., Kurokawa, M., Dagna, L., McClain, K. L., Mazor, R. D., Picarsic, J., Janku, F., Go, R. S., Haroche, J., & Diamond, E. L.
Venue
Blood
Published
2020-05-28
Volume
135
Issue
22
Pages
1929-1945
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3011169548
Cited by
416
References
59
FWCI
24.14
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. https://app.cochat.ai/papers/10.1182/blood.2019003507
The paper
Goyal, G., Heaney, M. L., Collin, M., Cohen-Aubart, F., Vaglio, A., Durham, B. H., Hershkovitz-Rokah, O., Girschikofsky, M., Jacobsen, E. D., Toyama, K., Goodman, A. M., Hendrie, P., Cao, X.-X., Estrada-Veras, J. I., Shpilberg, O., Abdo, A., Kurokawa, M., Dagna, L., McClain, K. L., . . . Diamond, E. L. (2020). Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. https://doi.org/10.1182/blood.2019003507

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.